semaglutide cardiovascular trial news lowers events even without major weight loss, researchers report Semaglutide and cardiovascular outcomes by

Williams is the latest in a series of high-profile athletes and celebrities to speak openly about using a weight-loss drug, often thanking it for major transformations

Yamane S, Harada N, Inagaki N

doi: 10.1038/s41467-021-24859-2 140 DaiEHanLLiuJXieYZehHJKangRet al

Topics of discussion will include: Monitoring, assessing, and ensuring adequate pharmacovigilance across GLP-1 drugs and manufacturing Flagging and remedying serious adverse effects associated with GLP-1s before facing suit Anticipating and preparing for MDLs and class actions Preempting issues caused by GLP-1 usage Afternoon Networking Break Phyllis Hurwitz MarcusVice President, National Advertising DivisionBBB National Programs Maria RisingInfluencerTirzepatide Tales & The Rising Project Claire DaviesShareholderPolsinelli From television to TikTok, from busses to subways, from podcasts to newspapers, it is impossible to escape GLP-1 advertisements in 2026

This pricing structure means stepping up to higher doses does not increase the base cost